DahLIA stands for the Dexmedetomidine to Lessen ICU Agitation study, which was a double-blind, placebo-controlled, RCT conducted at 15 ICUs in Australia and New Zealand from 2011 to 2013. The study aimed to determine how effective dexmedetomidine is in vented patients with delirium.
- dexmedetomidine (or placebo) was started at 0.5 ug/kg/h and titrated to rates between 0 to 1.5 to achieve sedation goals; drug was continued until no longer required or up to 7 days
- Outcomes include ventilator-free hours in the 7 days following randomization plus 21 secondary outcomes (see table below)
- 75 patients were enrolled, with 3 removed from study group – leaving 39 in treatment and 32 in placebo group
- dexmedetomidine significantly increased ventilator-free hours (144.8h vs 127.5h)
- dexmedetomidine significantly reduced time to extubation (21.9h vs 44.3h)
- dexmedetomidine significantly accelerated resolution of delirium (23.3h vs 40h)
Primary and Secondary Study Outcomes
Kaplan-Meier Analysis of the Proportion of Patients Remaining Intubated During the First 7 Days of the Study
Reade, Michael C. et al. “Effect Of Dexmedetomidine Added To Standard Care On Ventilator-Free Time In Patients With Agitated Delirium”. JAMA (2016): n. page.